AR101840A1 - Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene - Google Patents
Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contieneInfo
- Publication number
- AR101840A1 AR101840A1 ARP150102901A ARP150102901A AR101840A1 AR 101840 A1 AR101840 A1 AR 101840A1 AR P150102901 A ARP150102901 A AR P150102901A AR P150102901 A ARP150102901 A AR P150102901A AR 101840 A1 AR101840 A1 AR 101840A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- human papillomavirus
- seq
- gene
- gene encoding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un gen aislado que codifica la proteína de la cápside mayor del virus del papiloma humano, caracterizado porque dicho gen se selecciona entre SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4 y SEQ ID Nº 5. Reivindicación 2: Un vector que comprende el gen que codifica la proteína de la cápside mayor del virus del papiloma humano, caracterizado porque dicho gen se selecciona entre SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4, SEQ ID Nº 5, y su combinación. Reivindicación 6: Una célula huésped caracterizada porque comprende el vector tal como se reivindica en la reivindicación 2. Reivindicación 11: Una vacuna contra el virus del papiloma humano, caracterizada porque comprende al menos un gen que codifica la proteína del cápside entre las reivindicadas en la reivindicación 1, que puede generar una respuesta inmunitaria contra el antígeno del HPV. Reivindicación 16: Un método para preparar la vacuna contra el virus del papiloma humano tal como se reivindica en la reivindicación 11, caracterizado porque comprende los siguientes pasos: a) síntesis del gen que codifica la proteína de la cápside mayor del virus del papiloma humano; b) construcción del vector de expresión para el gen que codifica la proteína de la cápside mayor del virus del papiloma humano; c) selección del clon con un número alto de copias del gen transformado de dicha proteína del virus del papiloma humano; d) análisis de expresión del gen transformado de dicha proteína del virus del papiloma humano; e) purificación de la proteína codificada por el gen de dicha proteína del virus del papiloma humano; f) preparación de solución a granel de VLPs de dicha proteína del virus del papiloma humano; g) caracterización de dicha proteína en la célula huésped; h) preparación de la vacuna que contiene dicha proteína del virus del papiloma humano.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2905MU2014 | 2014-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101840A1 true AR101840A1 (es) | 2017-01-18 |
Family
ID=54843870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102901A AR101840A1 (es) | 2014-09-11 | 2015-09-11 | Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3191505A2 (es) |
JP (1) | JP2017528137A (es) |
CN (1) | CN107002085A (es) |
AR (1) | AR101840A1 (es) |
AU (1) | AU2015313756A1 (es) |
BR (1) | BR112017004181A2 (es) |
CA (1) | CA2958222A1 (es) |
EA (1) | EA201790365A1 (es) |
MA (1) | MA40624A (es) |
WO (1) | WO2016038625A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111154777B (zh) * | 2014-02-18 | 2023-08-15 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒蛋白表达 |
EP3365006A1 (en) | 2015-10-19 | 2018-08-29 | Cadila Healthcare Limited | New adjuvant and vaccine composition containing the same |
CN109750049B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒52亚型蛋白表达 |
EP3710468A1 (en) | 2017-11-14 | 2020-09-23 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Non-human papillomaviruses for gene delivery in vitro and in vivo |
US11389519B2 (en) * | 2018-06-11 | 2022-07-19 | Inventprise, Llc | Virus-like particle conjugates |
BR102020006846A2 (pt) * | 2020-04-03 | 2021-12-07 | Imunoscan Engenharia Molecular Ltda | Peptídeos sintéticos miméticos a proteína l1 do hpv, método de diagnóstico de hpv, sistema de diagnóstico de hpv, composição farmacêutica e uso dos mesmos no tratamento ou profilaxia do hpv |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2213185T3 (es) * | 1995-11-15 | 2004-08-16 | MERCK & CO., INC. | Particulas de tipo virus hpv11 sinteticas. |
ES2216280T3 (es) * | 1997-04-08 | 2004-10-16 | MERCK & CO., INC. | Formulaciones estabilizadas de papilomavirus humano. |
EP1700911B1 (en) * | 1997-09-05 | 2016-04-06 | Medimmune, Inc. | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs) |
MY140664A (en) * | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
JP4769247B2 (ja) * | 2004-06-18 | 2011-09-07 | インディアン・イムノロジカルズ・リミテッド | ヒトパピローマウイルス16型に対するSalmonellaワクチン株に関するコドン最適化されたHPV16L1 |
EP2223933B1 (en) * | 2007-11-23 | 2016-01-27 | Shanghai Zerun Biotechnology Co., Ltd. | Genes encoding major capsid protein l1 of human papilloma viruses |
CN101487009B (zh) * | 2008-01-15 | 2012-11-21 | 上海泽润生物科技有限公司 | 用毕赤酵母表达系统制备抗人乳头瘤病毒16型感染的疫苗的方法 |
JP6022159B2 (ja) * | 2008-07-31 | 2016-11-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 抗hpvワクチン |
WO2010147268A1 (ko) * | 2009-06-19 | 2010-12-23 | 아이진 주식회사 | 자궁경부암 백신 |
CN102154325B (zh) * | 2011-01-01 | 2013-08-21 | 上海生物制品研究所有限责任公司 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
AU2012255595A1 (en) * | 2011-05-13 | 2013-12-12 | Folia Biotech Inc. | Virus-like particles and process for preparing same |
JP6050811B2 (ja) * | 2011-06-24 | 2016-12-21 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | アルミニウムアジュバントを含むhpvワクチン製剤およびその産生方法 |
KR101559622B1 (ko) * | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
CN103667319B (zh) * | 2012-09-10 | 2017-09-26 | 同济大学 | 抗人乳头瘤病毒的三价疫苗及其制法和用途 |
-
2015
- 2015-09-11 EP EP15808033.3A patent/EP3191505A2/en not_active Withdrawn
- 2015-09-11 AU AU2015313756A patent/AU2015313756A1/en not_active Abandoned
- 2015-09-11 BR BR112017004181A patent/BR112017004181A2/pt not_active Application Discontinuation
- 2015-09-11 WO PCT/IN2015/000355 patent/WO2016038625A2/en active Application Filing
- 2015-09-11 EA EA201790365A patent/EA201790365A1/ru unknown
- 2015-09-11 JP JP2017513424A patent/JP2017528137A/ja active Pending
- 2015-09-11 CA CA2958222A patent/CA2958222A1/en not_active Abandoned
- 2015-09-11 CN CN201580049136.4A patent/CN107002085A/zh active Pending
- 2015-09-11 AR ARP150102901A patent/AR101840A1/es unknown
- 2015-09-11 MA MA040624A patent/MA40624A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2015313756A1 (en) | 2017-03-09 |
EA201790365A1 (ru) | 2017-07-31 |
WO2016038625A3 (en) | 2016-04-28 |
CN107002085A (zh) | 2017-08-01 |
BR112017004181A2 (pt) | 2017-12-05 |
WO2016038625A2 (en) | 2016-03-17 |
JP2017528137A (ja) | 2017-09-28 |
MA40624A (fr) | 2016-03-17 |
EP3191505A2 (en) | 2017-07-19 |
CA2958222A1 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR101840A1 (es) | Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene | |
CO2018005265A2 (es) | Vacunas de ácido nucleico para el virus varicela-zóster | |
PH12017500727A1 (en) | Modified virus-like particles of cmv | |
MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
MX2024009690A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
CO2017004838A2 (es) | Vacunas terapéuticas contra el vph16 | |
PH12015502790A1 (en) | Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof | |
AR102006A1 (es) | Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos | |
EA201201025A1 (ru) | Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них | |
PH12019500591A1 (en) | Canine adenovirus vectors | |
AR101468A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
PH12019500578A1 (en) | New promoters | |
PH12019500557A1 (en) | New ehv insertion site orf70 | |
CY1118704T1 (el) | Ανθρωπινος πληθυσμος βλαστοκυτταρων του τραχηλου της μητρας και χρησεις αυτου | |
NZ719934A (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
MX2013013228A (es) | Particulas similares a virus y proceso para prepararlas. | |
PH12020500526A1 (en) | Paramyxoviridae expression system | |
MX2019007924A (es) | Vacunas contra la influenza. | |
EA202092164A1 (ru) | Новый ehv с инактивированным ul18 и/или ul8 | |
AR092939A1 (es) | Vacuna contra cooperia | |
WO2012001196A3 (es) | Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |